AMTA
GenericsAMTA is a generic drug manufacturer focused on Neurology, Immunology, Gastroenterology.
AMTA's Key Drugs
AMTA's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
AMTA's Recent FDA Approvals
New NDA/BLA approvals for AMTA over the last two years — novel drugs only, excluding generics and label supplements.
AMTA's Therapeutic Areas
AMTA's approved drugs and pipeline span 4 therapeutic areas, led by Neurology and Immunology. Weighted by commercial stage — approved drugs count most, then late-stage trials.
AMTA's Top Competitors
AMTA's closest competitors by therapeutic-area and drug-target overlap include WARNER CHILCOTT, Bristol-Myers Squibb, and BAUSCH. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
AMTA Pipeline Snapshot
Active clinical trials for AMTA across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Neurology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 2020-01-06
- Latest
- 2026-01-18
- Applications
- 5